Compare AL & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AL | COGT |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | 160 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.5B |
| IPO Year | N/A | 2018 |
| Metric | AL | COGT |
|---|---|---|
| Price | $64.71 | $37.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $62.50 | $33.50 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,871,000.00 |
| Revenue This Year | $5.78 | N/A |
| Revenue Next Year | $5.58 | $506.58 |
| P/E Ratio | $6.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.25 | $3.72 |
| 52 Week High | $64.97 | $43.73 |
| Indicator | AL | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 52.23 | 47.18 |
| Support Level | $63.44 | $36.52 |
| Resistance Level | $64.97 | $41.02 |
| Average True Range (ATR) | 0.11 | 1.84 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 19.70 | 35.35 |
Air Lease Corp is an aircraft leasing company based in the United States. It is engaged in the modern, fuel-efficient new technology commercial jet aircraft directly from aircraft manufacturers and leasing those aircraft to airlines throughout the world to generate attractive returns on equity. The company also sells aircraft from its fleet to third parties, including other leasing companies, financial services companies, airlines, and other investors, and offers fleet management services to investors and owners of aircraft portfolios for a management fee. Geographically, it derives a maximum of its revenue from the Europe and the rest from Asia Pacific, Middle East and Africa, Central America, South America, Mexico, the United States, and Canada.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.